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Objectives:
 
 To describe a method for measuring the di-
rect and indirect costs to families of infants hospitalized
with respiratory syncytial virus (RSV).
 
Methods:
 
 After pretesting and revising a questionnaire,
a prospective survey was conducted in multiple tertiary-
care hospitals with pediatric intensive care units. Eligi-
ble patients were infants less than 12 months old who
had not received RSV prophylaxis and were hospital-
ized with a confirmed RSV infection. All English- and
Spanish-speaking caregivers of eligible subjects were
asked to participate in a face-to-face, structured inter-
view on the day of hospital discharge regarding hospi-
talization-related direct and indirect costs. Thirty days
later, caregivers were re-interviewed by telephone about
their RSV-related costs during the elapsed month. The
survey was initiated in February 2000 and continued
through April 2001.
 
Results:
 
 In addition to the infants’ parents, numerous
adults visited 55% of hospitalized infants. In 17% of
cases, nonparents missed work to visit the child. Volun-
teers watched siblings of 26% of the infants. Relying
only on closed-ended questions about parents’ costs
during the hospitalization would have missed impor-
tant information about child-care volunteers and types
of expenses. Follow-up interviews revealed that RSV-
related out-of-pocket expenses and missed work contin-
ued during the month following discharge.
 
Conclusions:
 
 Survey instruments should be pretested
with potentially eligible subjects. Open-ended questions
are needed, because all costs cannot be anticipated. Re-
spondents should be probed for details. This method re-
vealed certain time and financial burdens during and af-
ter hospitalization that had not been previously reported
in the literature.
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Introduction
 
Childhood disease caused by respiratory syncytial
virus (RSV) provides an excellent model for study-
ing the financial burden of pediatric hospitalization
on families. RSV is the most common cause of
bronchiolitis and pneumonia in infants and young
children, according to the US Centers for Disease
Control [1]. One recent study estimated that hospi-
talization rates for bronchiolitis in children younger
than 1 year old increased dramatically between
1980 and 1996 from 12.9 to 31.2 per 1000.
Among children younger than 1 year old, RSV was
estimated to be the etiologic agent annually in
51,240–81,985 bronchiolitis discharges and 22,160–
44,321 pneumonia discharges between 1994 and
1996 [2]. Hospitalization risks are highest for spe-
cific groups of infants: those born prematurely;
those with underlying risk factors such as chronic
lung disease or congenital heart disease, and those
with a compromised immune system.
Two products, respiratory syncytial virus im-
mune globulin intravenous (RSV-IGIV, RespiGam
 
®
 
,
MedImmune, Inc., Gaithersburg, MD) and palivi-
zumab (Synagis
 
®
 
, MedImmune), are approved by
the US Food and Drug Administration for passive
prophylaxis against RSV-associated hospitalization
in high-risk infants. Palivizumab, the major prod-
uct currently used, is administered by intramuscu-
lar injection. Each product is administered monthly
during the RSV season, which runs approximately
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from fall through early spring in most of the United
States.
The American Academy of Pediatrics has issued
guidelines for the use of RSV prophylaxis. While
these guidelines focus primarily on infants with
chronic lung disease of infancy or those born at or
before 32 weeks of gestation, otherwise healthy
infants born at 32 to 35 weeks of gestation with
additional risk factors are included [3].
There is mounting evidence that palivizumab is
safe and highly effective in reducing hospitalization
rates in high-risk infants [4,5]. However, some ex-
perts believe that RSV prophylaxis should be lim-
ited to infants born at or before 32 weeks of gesta-
tion on the basis of cost, approximately $1000 per
month, depending on the infant’s weight. They
point to studies showing that the cost to avoid an
RSV hospitalization increases sharply with gesta-
tional age. Joffe et al. [6] estimated it would cost
more than $35,000 to avoid an RSV hospitaliza-
tion in infants born between 33 and 36 weeks of
gestation and concluded that prophylaxis was
cost-ineffective for that cohort of premature in-
fants. Stevens et al. [7] estimated the incremental
cost to avoid an RSV hospitalization in infants
born up to 32 weeks of gestation. They concluded
that it would cost $18,183 for infants born up to
26 weeks of gestation compared with $72,712 for
the 31- to 32-week gestational age group.
Cost-effectiveness analyses should be performed
from a societal perspective and should incorporate
all direct and indirect costs (including pain and
suffering, lost productivity, and outpatient costs)
[8]. However, the cost of RSV prophylaxis to date
has been primarily compared with the hospital
charge for an RSV-associated inpatient stay [9].
Very little information about the actual financial
burden on families associated with RSV hospitaliza-
tion has been published. No economic analysis of
RSV in the United States has included all related
medical resources associated with an acute episode
entailing a hospital stay. Only inpatient hospital
costs or charges have been included. The study of
managed-care enrollees by Joffe et al. [6] included
only the cost of parental work loss based on the as-
sumption that one parent would stay with their hos-
pitalized child and/or travel to obtain prophylaxis
during an office visit. No additional time or out-
of-pocket costs were assumed. The researchers did
not test their assumptions with the families whose
medical records were used for the retrospective data
analysis. An improved method for capturing all rel-
evant costs associated with an acute episode of RSV
infection entailing hospitalization is needed.
 
Objective
 
We describe the method used and some lessons
learned from a survey to measure time burden and
out-of-pocket expenses reported by primary care-
givers of infants hospitalized between February
2000 and April 2001 with laboratory-confirmed
RSV infection. This study focuses on the financial
burden borne by families of infants born at 33 to
35 weeks of gestation during hospitalization for
RSV infection and the first 30 days following dis-
charge. The potential application of this approach
to economic studies of other pediatric illnesses re-
quiring hospitalization is discussed.
 
Methods
 
A prospective survey of parents and/or caregivers
of hospitalized infants was conducted in multiple,
geographically dispersed, urban tertiary-care hos-
pitals with pediatric intensive care units. The study
was intended to be descriptive and is not represen-
tative of the universe of potential subjects. A max-
imum of 200 subjects could be enrolled. For the
purpose of comparison, up to 50 full-term infants
with RSV could also be enrolled at one of the
study hospitals. The institutional review board of
each participating hospital or affiliated academic
institution approved the study.
Before commencement of the survey, a draft set
of closed-ended questions was pretested with po-
tentially eligible parents of hospitalized infants.
During the pretest, parents were asked if the ques-
tions were clear and understandable and if the sur-
vey captured all relevant costs they and other af-
fected adults had incurred during the course of the
hospitalization. Based on their responses and fol-
lowing extensive probing, the survey instrument
was refined. For example, the survey initially asked
the informant to report his or her own and one
other parent/caregiver’s experiences. Based on the
results of the pretest, we discarded the assumption
that only parents incurred time and monetary
costs from the hospitalization of their infant. We
revised the survey to ask the total number of
adults who came to the hospital. To limit the
length and duration of the survey, we asked about
the time and out-of-pocket costs of up to five
adults 
 
seriatim.
 
 We added the question, “Did you
take any time off from work because your baby
was in the hospital?” We also added an open-
ended question; “Did you or other caregivers have
any additional expenses you didn’t mention yet
because the baby was in the hospital (excluding
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medical or hospital bills)?” Table 1 lists categories
of expenses in the survey instrument.
A daily patient census was taken to identify all
pediatric inpatients less than 1 year old born be-
tween 33 and 35 weeks of gestation, hospitalized
with a laboratory-confirmed RSV infection, who
had not received either RSV-IGIV or palivizumab,
and were not then subjects in a clinical trial. All
such infants were eligible for inclusion in the study.
Following informed consent, demographic, diag-
nostic, and insurance-source data were abstracted
from the infant’s medical and hospital records.
Also recorded were the infant’s admission and dis-
charge dates and whether the infant was admitted
to the intensive care unit. Infants born later than
35 weeks of gestation and less than 1 year old
were enrolled at one site using identical methods
for comparison.
A primary caregiver of each eligible infant was
told, “We’re doing a study about sick children like
yours and their families. We would like to know
more about what happens to families when their
babies have to stay in the hospital,” and asked
them to tell us in confidence about their recent ex-
perience. Caregivers unable to understand or com-
municate in either English or Spanish were ex-
cluded from the study. A trained staff physician or
research nurse privately interviewed caregivers in
English or Spanish on the day of the infant’s
planned discharge. Respondents were offered $25
for the face-to-face hospital interview and an addi-
tional $25 for the follow-up telephone interview
at 30 days post-discharge. A standardized printed
survey was used for both interviews. Interviewers
were instructed to obtain responses to all applica-
ble questions and to record verbatim responses.
Information gathered was assumed to be reli-
able unless it was illogical on its face or inconsis-
tent with information from the patient’s record.
Post-discharge information was accepted as re-
ported by the caregiver.
 
Results
 
We reviewed completed surveys from 36 full-term
and 49 premature infants. Caregivers reported in-
curring time and monetary costs associated with
travel and time spent in the hospital, missed work,
parking fees, hospital meals, payments for child care,
copayments for doctor visits, and prescriptions.
Sixty percent of the premature infants and 47% of
the full term infants (55% overall) were visited by
both parents plus numerous other adults, includ-
ing grandparents, aunts and uncles, and friends.
Nonparental visitors to 17% of the infants missed
work to go to the hospital. Respondents also re-
ported additional costs such as lost wages and
productivity by employed friends and relatives who
came to the hospital and/or provided unpaid child
care for siblings. Siblings of 26% of hospitalized
infants received free care from relatives and 14%
of the respondents reported that these volunteers
took time off from work to provide this. Other re-
ported costs included emergency room visits be-
fore the hospital admission, ambulance fees to trans-
fer an infant from another hospital, and loss of
income from small businesses. Some respondents
reported relevant nonreimbursed out-of-pocket costs
such as: humidifiers and apnea monitors for their
sick infant’s room in the hospital and at home;
kennel fees for the family dog; infant formula be-
cause the nursing mother ceased lactation during
the hospital stay; and loss of a full college scholar-
ship by a parent who couldn’t complete college
course work during the infant’s extended illness.
During follow-up interviews, 15% of respondents
also reported lost income and missed work because
of ongoing RSV-related illness after discharge. In
fact, 8% of the infants were readmitted to the hos-
pital because of RSV infection during the follow-
up period.
 
Discussion
 
This is the first study in the United States that asks
families directly about time and monetary costs
associated with a confirmed RSV hospitalization
of their infant. One small retrospective survey of
parent/caregivers of 43 infants hospitalized with
 
Table 1
 
Categories of direct and indirect costs associated 
with pediatric RSV infection
 
For respondent and up to four other caregivers:
A. During hospitalization:
Travel time and cost, including parking
Hotel/motel costs
Meals
Employment status & time off from full/part time work
Time spent in the hospital
Child-care additional costs
Any additional expenses
B. Month post-discharge
Travel time and costs (including copays) RSV-related outpatient
visit
Cost of physician-ordered food, supplies, or equipment
Other RSV-related expenses, including nonprescription
medication
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presumed RSV compared transportation and child
care out of pocket expenses as well as lost work
time and wages among parents of infants who had
or had not received RSV-IGIV prophylaxis. Par-
ents of infants who had not received RSV-IGIV re-
ported higher transportation expenses and greater
lost wages as a result of increased use of ambula-
tory and hospital services, but reported slightly
lower child-care costs than were reported for in-
fants who received prophylaxis [10]. The study
concluded that total average costs were lower for
infants given RSV-IGIV. However, these results
are difficult to generalize to the population of vul-
nerable infants for whom palivizumab prophy-
laxis may be indicated. The study did not inquire
about the value of contributed labor or the time
and monetary costs incurred by adults other than
the parents of the hospitalized infant.
The scope of costs reported by respondents in
our small survey exceeds those included in pub-
lished RSV-specific cost-effectiveness studies, and,
to our knowledge, many of the expenses identified
have not been reported in cost-effectiveness analy-
ses of interventions for other childhood diseases.
The current debate over the cost-effectiveness of
RSV prophylaxis is handicapped by the narrow
definition of costs to be measured. The best way to
capture the actual economic burden of hospitalized
children on society and on their families is to ask a
combination of closed- and open-ended questions
about time, lost productivity, lost income, and item-
ized out-of-pocket expenses incurred by all adults
involved in the care of the sick infant. Financial im-
plications and time requirements of arrangements
made specifically to care for healthy siblings should
also be included. Potential questions regarding spe-
cific costs should be pretested with eligible respon-
dents to verify their relevance and completeness.
Respondents should be encouraged to speak at
length about their experiences. These anecdotes
may provide useful reality checks for researcher’s
assumptions about the financial and social burden
of childhood illness. Because it is difficult to pre-
specify all categories of potential costs incurred, an
open-ended question should be asked so that any
unexpected additional costs are captured before
concluding the interview.
Pretests of the draft survey instrument led us to
conclude that measuring lost productivity of only
one parent may artificially deflate estimates of this
dimension of social burden of illness, because a di-
verse network of relatives and friends may be mobi-
lized to respond when an infant is hospitalized. Our
results confirm this conclusion. Had we limited our
 
questions to the parent’s own experiences and not
given them the opportunity to describe the impact
of the hospitalization on other concerned adults,
important cost information would have been missed.
If one collects information limited to the out-of-
pocket cost for additional child care, one would fail
to capture the societal value of contributed labor
(and lost income) by volunteers who enable parents
to remain with the hospitalized infant. For exam-
ple, if only a “yes” or “no” response to the ques-
tion regarding payment for altered child care for
siblings during the hospitalization had been col-
lected, it would not have been possible to conclude
that many adults donated labor and some lost in-
come to watch over the siblings.
Obtaining information about employment sta-
tus, time off from work, travel time, duration of
hospital visits, and time and monetary cost of car-
ing for siblings permits the researcher to estimate
the societal value of that time using a variety of
standard methods such as average hourly wages
and replacement cost. The self-employed and those
not paid for sick leave reported losing substantial
income, and that loss can also be considered from
the family’s perspective. In certain instances, the
cost of meals and parking at hospitals may be sub-
stantial. At one urban hospital, parents are encour-
aged and expected to remain with their sick chil-
dren on a continuous basis but are not provided
with any food and have to pay each time they re-
enter the parking garage. Another hospital charged
parents for overnight stays, a practice that we were
not aware of and that would not have been cap-
tured by asking only for the cost of hotel or motel
stays. Furthermore, to assume that the costs in-
curred by families end at the time of discharge will
fail to capture the costs of ongoing medical care
provided by families and which results in addi-
tional loss of wages and productivity as well as
nonreimbursed medical and nonmedical costs. We
had expected parent’s lost work time to be associ-
ated only with a follow-up visit to the doctor.
However, some of the patients were rehospitalized
for RSV during the follow-up month, and those
costs were not captured by the questionnaire.
Further refinement of the methodology could
have been achieved by asking explicitly how much
of the total time reported for travel and visits to
the hospital was time that would otherwise have
been consecrated to work. Although respondents
were asked specifically whether they took any time
off from work, this should have been followed up
with a question about the exact number of work
hours missed. Some respondents volunteered that
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information, but it was not gathered systemati-
cally. Information regarding the total amount of
lost income should also have been collected, be-
cause not all employed respondents received sick
pay for their leave. Information about the nature
of respondent’s work may not have been helpful,
because it is difficult to categorize job descriptions
for the purpose of estimating different wage re-
placement rates. Finally, an explicit question about
the total number of adults who provided unpaid
child care for siblings should have been included,
given that some respondents reported that several
people were involved.
In the follow-up interview, explicit questions
regarding work time lost because of the infant’s
ongoing illness should have been asked. It was as-
sumed, erroneously, that once discharged, infants
would be healthy enough for parents to resume
their normal activities. It would also have been ap-
propriate to capture costs associated with rehospi-
talization during the month following discharge.
To our knowledge, no study of RSV-associated
costs has quantitatively evaluated costs of prehos-
pitalization medical services. Because several re-
spondents indicated that they had sought medical
care for their infant’s symptoms before admission,
we recommend that future studies take these costs
into account. Furthermore, some of the infants
were transferred from another hospital, and that
earlier portion of their acute illness was not cap-
tured in this survey.
Failure to measure all direct and indirect medi-
cal and nonmedical costs associated with the hos-
pitalization of a child may lead to underestimation
of the cost-effectiveness of prophylaxis or novel
therapies from a societal perspective. While not
everyone may agree whether and how to place a
monetary value on each itemized expense reported
by caregivers, it is important to ascertain what a
family considers to be relevant to a specific epi-
sode of illness.
This survey instrument has not been formally
validated and, as with any post hoc survey, there
may be recall bias. It is difficult to independently
verify the reliability and validity of most responses.
Reports about time are checked for internal logic
and face validity. For example, time spent in the
hospital should not exceed the length of stay de-
rived from the patient’s record. Reports of follow-
up visits to physicians and prescriptions filled
were not confirmed directly with the physician’s
office or the dispensing pharmacy. While such ver-
ification may increase the accuracy of certain re-
sults, it would also significantly increase the cost
and difficulty of conducting the study. Reported
out-of-pocket expenses and lost income would be
difficult to verify. On the other hand, basing cost-
effectiveness studies on researcher’s assumptions
about costs to families and society also introduces
an unknown degree of bias.
The authors believe that the use of open-ended
questions is a useful method for collecting data
about the cost-effectiveness of a medical intervention
aimed at children from a societal perspective. Indeed,
this method could be applied to health-care interven-
tions beyond those associated with the evaluation of
costs associated with RSV hospitalization, and we
would encourage further study in this area.
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